Cambridge Healthtech Institute, Aug 2010, Pages: 320
. Goldfarb is Managing Director of First Clinical Research LLC, a provider of clinical research best practices information, consulting and training services. Bio/PharmaR&D Statistical Sourcebook 2010/2011
Global Markets Direct, Nov 2011, Pages: 96
targets and therapeutic classes in the Array BioPharma Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying
GlobalData, Nov 2010, Pages: 30
in the Limerick BioPharma, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill
Global Markets Direct, Nov 2010, Pages: 30
in the Limerick BioPharma, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill
Global Markets Direct, Nov 2011, Pages: 90
classes in the AVI BioPharma Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity
GlobalData, Nov 2010, Pages: 30
in the LTT Bio-Pharma Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill
Global Markets Direct, Nov 2010, Pages: 30
in the LTT Bio-Pharma Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill
Global Markets Direct, March 2011, Pages: 72
on its product pipeline.
- Assess the growth potential of PDL BioPharma, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the PDL BioPharma, Inc.’s R&D portfolio
Global Markets Direct, March 2011, Pages: 33
in the Synageva BioPharma Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill
Global Markets Direct, Sep 2011, Pages: 46
.
- Identify new drug targets and therapeutic classes in the CeNeRx BioPharma, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing
Global Markets Direct, April 2011, Pages: 57
&D Progress
Cannabinoid-045
Product Description
Mechanism of Action
R&D Progress
CeNeRx BioPharma, Inc. – Pipeline Analysis
CeNeRx BioPharma, Inc. – Pipeline Products by Therapeutic Class
Global Markets Direct, Dec 2010, Pages: 69
.
- Assess the growth potential of AVI BioPharma Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the AVI BioPharma Inc.’s R&D portfolio and develop key strategic
GlobalData, Nov 2010, Pages: 25
of focus.
- Identify new drug targets and therapeutic classes in the Canopus BioPharma Incorporated’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit
Global Markets Direct, Nov 2010, Pages: 25
of focus.
- Identify new drug targets and therapeutic classes in the Canopus BioPharma Incorporated’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit
Global Markets Direct, Nov 2010, Pages: 47
Modalities
Oncolys BioPharma Inc. – Drug Profiles
Festinavir
Product Description
Mechanism of Action
R&D Progress
Telomelysin
Product Description
Mechanism of Action
R
GlobalData, Nov 2010, Pages: 39
in the Can-Fite BioPharma Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill
Global Markets Direct, Nov 2010, Pages: 39
in the Can-Fite BioPharma Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill
GlobalData, Sep 2011, Pages: 38
Pronova BioPharma ASA (PRON) - Financial and Strategic SWOT Analysis Review
Summary
Pronova BioPharma ASA (Pronova BioPharma) is a biotechnology company engaged in the research, development
